SignalHF vs Fetal EchoScan
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
SignalHF is designed for predicting heart failure hospitalizations in adults by analyzing data from cardiac implantable devices, enabling proactive management. Fetal EchoScan, however, focuses on assisting clinicians in the prenatal detection of congenital heart defects using AI-powered ultrasound screening. While both are FDA-cleared AI tools in cardiology, they serve distinct patient populations and clinical objectives, making them suitable for different stages of cardiac care.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
SignalHF by Implicity is an FDA-cleared AI algorithm designed to predict heart failure hospitalizations within 30 days by analyzing data from cardiac implantable electronic devices. Fetal EchoScan by Brightheart is an FDA-cleared AI-powered ultrasound screening software that assists clinicians in the prenatal detection of congenital heart defects.
SignalHF analyzes physiological data, demographics, lead measurements, episodes, and therapies from various cardiac implantable electronic devices (CIEDs) such as pacemakers, ICDs, and CRTs. Fetal EchoScan, on the other hand, analyzes fetal cardiac ultrasound video clips, specifically 4-chamber, left ventricular outflow tract, and right ventricular outflow tract standard views, to detect suspicious radiographic findings.
SignalHF is primarily designed for cardiology specialists, particularly those involved in cardiac remote monitoring. Fetal EchoScan is intended for use by interpreting physicians in Cardiology, Maternal-Fetal Medicine, and Radiology, serving as an adjunct to the interpretation of second-trimester fetal anatomic ultrasound exams.
SignalHF offers a unified platform for centralizing cardiac implantable device data and generates automatic alerts for care teams based on risk scores, enabling early intervention. Fetal EchoScan integrates with existing ultrasound workflows, providing real-time guidance and feedback during ultrasound scans and displaying AI analysis and alerts on a cart-side tablet.
SignalHF aims to revolutionize heart failure care by enabling early intervention and personalized care plans, potentially averting hospitalizations and improving patient outcomes through its predictive AI. Fetal EchoScan's benefits include ensuring exam completeness, standardizing fetal heart assessments, and reducing false-negative and false-positive errors in congenital heart defect detection, leading to optimized workflow and faster reading times.
SignalHF specifically predicts heart failure hospitalizations within 30 days. Fetal EchoScan assists in the prenatal detection of congenital heart defects (CHDs) by identifying suspicious radiographic findings such as septal defects, abnormal outflow tract relationships, and cardiac axis deviation.